Advertisement
Small Molecule Therapeutics

Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas

Long-Sheng Chang, Janet L. Oblinger, Sarah S. Burns, Jie Huang, Larry W. Anderson, Melinda G. Hollingshead, Rulong Shen, Li Pan, Garima Agarwal, Yulin Ren, Ryan D. Roberts, Barry R. O'Keefe, A. Douglas Kinghorn and Jerry M. Collins
DOI: 10.1158/1535-7163.MCT-19-0809 Published March 2020

Abstract

Malignant peripheral nerve sheath tumors (MPNST) frequently overexpress eukaryotic initiation factor 4F components, and the eIF4A inhibitor silvestrol potently suppresses MPNST growth. However, silvestrol has suboptimal drug-like properties, including a bulky structure, poor oral bioavailability (<2%), sensitivity to MDR1 efflux, and pulmonary toxicity in dogs. We compared ten silvestrol-related rocaglates lacking the dioxanyl ring and found that didesmethylrocaglamide (DDR) and rocaglamide (Roc) had growth-inhibitory activity comparable with silvestrol. Structure–activity relationship analysis revealed that the dioxanyl ring present in silvestrol was dispensable for, but may enhance, cytotoxicity. Both DDR and Roc arrested MPNST cells at G2–M, increased the sub-G1 population, induced cleavage of caspases and PARP, and elevated the levels of the DNA-damage response marker γH2A.X, while decreasing the expression of AKT and ERK1/2, consistent with translation inhibition. Unlike silvestrol, DDR and Roc were not sensitive to MDR1 inhibition. Pharmacokinetic analysis confirmed that Roc had 50% oral bioavailability. Importantly, Roc, when administered intraperitoneally or orally, showed potent antitumor effects in an orthotopic MPNST mouse model and did not induce pulmonary toxicity in dogs as found with silvestrol. Treated tumors displayed degenerative changes and had more cleaved caspase-3–positive cells, indicative of increased apoptosis. Furthermore, Roc effectively suppressed the growth of osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma cells and patient-derived xenografts. Both Roc- and DDR-treated sarcoma cells showed decreased levels of multiple oncogenic kinases, including insulin-like growth factor-1 receptor. The more favorable drug-like properties of DDR and Roc and the potent antitumor activity of Roc suggest that these rocaglamides could become viable treatments for MPNST and other sarcomas.

This article is featured in Highlights of This Issue, p. 729

Introduction

Malignant peripheral nerve sheath tumors (MPNST) are characterized as aggressive soft-tissue sarcomas with a high risk of recurrence and metastasis. Often refractory to current treatment, patients with these tumors have a poor 5-year survival rate of only about 20% to 50% (1). Therefore, development of a more effective medical therapy that eradicates MPNSTs is of significant clinical need. MPNSTs can occur sporadically or arise from preexisting plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1), a tumor predisposition syndrome caused by mutations in the NF1 gene which encodes the Ras-GTPase–activating protein neurofibromin. Importantly, even sporadic tumors frequently harbor mutations in the NF1 gene or the Ras pathway. Consequently, both sporadic and NF1-associated MPNSTs exhibit upregulation of Ras downstream kinase signaling, including the PI3K–AKT–mTOR and Raf–MEK–ERK mitogen-activated protein kinases. MPNSTs also exhibit overexpression or aberrant activation of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and insulin-like growth factor-1 receptor (IGF-1R; refs. 2, 3). These reports suggest that these Ras downstream kinases and deregulated receptor tyrosine kinases (RTKs) may be therapeutic targets. In addition, recurrent mutations in the tumor-suppressor genes CDKN2A and TP53 and the subunits of the chromatin-modifying polycomb repressor complex-2 (PRC2), SUZ12 and EED, have been identified and are important for MPNST progression (4). Inactivation of CDKN2A and TP53 disables the G1–S checkpoint. The loss of PRC2 function can lead to enhanced Ras-driven gene transcription (5).

As MPNSTs often exhibit hyperactive Ras activity, statins and farnesyl transferase inhibitors, which prevent localization of Ras to the membrane and inhibit MPNST cell growth (6, 7), have been evaluated but do not improve survival in patients with advanced cancer (8–10). Drugs that target the deregulated RTKs and mitogenic kinases have also been investigated in patients with MPNSTs; however, the results have so far been disappointing. The EGFR inhibitor erlotinib elicited poor response rates in MPNSTs with only 1 of 20 patients exhibiting stable disease (11). The IGF-1R–blocking antibodies, such as ganitumab, show limited objective single-agent activity (12). Sorafenib, which inhibits Raf and several RTKs, has only minimal activity in patients with sarcomas (13). The mTOR inhibitor rapamycin and its derivatives, such as everolimus, cause cytostatic responses and are being evaluated in combination with other targeted drugs. However, a recent trial showed that combination of everolimus with bevacizumab, a monoclonal antibody that binds VEGF and prevents activation of the RTK VEGF receptor, was not effective in patients with refractory MPNSTs (14). A phase II study is ongoing to evaluate the dual mTOR complexes 1 and 2 inhibitor TAK-228 in soft-tissue sarcomas (https://clinicaltrials.gov Identifier: NCT02987959). Collectively, the modest and transient patient responses from the completed trials indicate that targeting more than one critical pathway is likely needed to achieve a cure.

To sustain uncontrolled growth, cancer cells commonly exhibit enhanced protein translation by upregulation of the translation machinery (15). The most highly regulated step in the protein biosynthetic pathway occurs during translation initiation, in which the eukaryotic initiation factor 4F (eIF4F) complex is recruited to the 5′ untranslated region (5′-UTR) of mRNA. This complex is composed of three subunits: eIF4G, a scaffolding protein; eIF4E, a cap-binding protein; and eIF4A, an RNA helicase which unwinds the secondary structure of the 5′-UTR. We have shown overexpression of the three eIF4F components in multiple types of human cancer, including MPNST (16, 17). Genetic inhibition of eIF4A and eIF4E using short-hairpin RNAs reduces MPNST cell proliferation. In addition, the prosurvival and progrowth activities of several signaling pathways, such as PI3K–AKT–mTOR and Raf–MEK–ERK frequently activated in human cancer, occur in part by facilitating eIF4F-mediated translation initiation. The mTOR kinase phosphorylates and inactivates the eIF4E-binding protein translational repressors (18). Both AKT and ERKs phosphorylate eIF4B, which then associates with and increases the helicase activity of eIF4A (19). Moreover, AKT, mTOR, and the downstream ERK1/2 kinase, p90 ribosomal S6 kinase, can phosphorylate and inactivate an endogenous repressor of eIF4A activity, the programmed cell death 4 protein. Further, the mRNAs that depend upon eIF4A for efficient translation usually contain long 5′-UTRs with guanine-rich sequences termed G-quadruplexes which can form four-stranded structures with G-tetrads stacked on one another (15). These eIF4A-dependent transcripts are often found in genes encoding oncoproteins, transcription factors associated with super enhancers, epigenetic regulators, and kinases (20). Interestingly, we found that the eIF4A inhibitor silvestrol suppresses MPNST cell growth at low nanomolar of IC50, decreases the levels of multiple mitogenic kinases including AKT and ERKs, and profoundly impairs the growth of MPNST xenografts (16). These results suggest that direct targeting of the translation initiation components, particularly eIF4A, might be an effective treatment strategy for these tumors.

Silvestrol is part of a large family of compounds termed flavaglines or rocaglates, which share a cyclopenta[b]benzofuran structure (21, 22). It possesses potent antitumor activity in multiple other cancer models (23–25). However, silvestrol has some suboptimal drug-like properties. It is relatively large with a bulky dioxanyl ring, making the total synthesis of silvestrol laborious (26–28). It is a substrate for the multidrug resistance 1 (MDR1) transporter (29) and has very limited oral bioavailability of <2% (30).

To search for compounds with better drug-like properties, we analyzed ten rocaglates that lack the dioxanyl moiety and examined the structure–activity relationships for this compound class. We showed that two of these compounds, rocaglamide (Roc) and didesmethylrocaglamide (DDR), exhibited potent growth inhibitory activity with IC50 values comparable to silvestrol. Importantly, these rocaglamides were not sensitive to MDR1 inhibition, and Roc exhibited oral bioavailability and potent antitumor effects against multiple types of sarcomas.

Materials and Methods

Natural compounds

Ten silvestrol-related rocaglates, inclusive of (−)-didesmethylrocaglamide, were isolated from the tropical plant Aglaia perviridis, collected in Vietnam as part of a multi-institutional collaborative project on the discovery of new antineoplastic natural compounds. The full structures and absolute configurations of these rocaglates were determined (31). For in vitro studies, purified silvestrol and related rocaglates were dissolved as a 10 mmol/L stock in DMSO (Sigma-Aldrich). A 60-mg sample of (−)-rocaglamide (NSC326408) was prepared at the U.S. National Cancer Institute for in vivo studies.

Cell lines, cell proliferation assays, and flow cytometry

Various MPNST, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, schwannoma, meningioma, and leukemia cell lines used in this study are described in Supplementary Methods. All cell lines were authenticated by short tandem repeat genotyping and tested to be mycoplasma-free. Cell proliferation was assessed using resazurin assays, and cell-cycle analysis was performed as previously described (32).

Western blots

Subconfluent cells were treated with the indicated doses of Roc or DDR for 1 to 3 days and lysed. Equal amounts of protein lysates were analyzed by immunoblotting. Detailed procedures and the antibodies used are described in Supplementary Methods.

Pharmacokinetic analysis

Mice were administered with a 5 mg/kg dose of Roc by i.v. or i.p. injection or by oral gavage (p.o.). Blood samples were collected before and at multiple time-points after dosing (n = 3). Plasma concentrations of Roc were analyzed using a sensitive LC/MS-MS (Supplementary Methods).

Cell line–derived xenograft and patient-derived xenograft models and in vivo efficacy

All animal work was performed according to the protocols approved by the Institutional Animal Care and Use Committee at Nationwide Children's Hospital. For animal dosing, Roc was formulated in 30% hydroxypropyl-β-cyclodextrin (HPβCD). The quantifiable, orthotopic MPNST cell line–derived xenograft (CDX) model was generated as described previously (33). Mice bearing established ST8814-Luc tumors (16) were randomized into three groups (n = 10/group) and treated with the predetermined MTD of Roc at 4 mg/kg by i.p. or 1.2 mg/kg by oral gavage, or the vehicle HPβCD every other day. Tumor growth was measured weekly by bioluminescence imaging (BLI).

To generate patient-derived xenograft (PDX) models, the Nationwide Children's Hospital Institutional Review Board approved the Human Subjects Protocol. After obtaining informed written consents from the subjects, tumor specimens were used to establish PDX models. Mice with actively growing PDX tumors for a Ewing sarcoma (NCH-EWS-2), an osteosarcoma (NCH-OS-7), and an alveolar rhabdomyosarcoma (NCH-ARMS-2) reaching approximately 100 to 200 mm3 were randomized into two treatment groups (n = 10/group) for each PDX model and treated with 3 mg/kg of Roc or HPβCD by i.p. every other day, followed by tumor measurement twice weekly (Supplementary Methods).

Immunohistochemistry

Sections from Roc or vehicle-treated MPNST tumors were prepared and stained with hematoxylin and eosin (H&E) or immunostained for p-histone H3(Ser10) (pH3; ab32107, Abcam) or CC3 (#9664, Cell Signaling Technology) as previously described (32).

Results

DDR and Roc possess potent growth-inhibitory activity comparable with silvestrol

To search for compounds with better drug-like properties, we side-by-side compared ten rocaglates lacking the dioxanyl ring (31) with silvestrol for growth-inhibitory activity in a panel of MPNST, schwannoma, and meningioma cell lines, which we previously showed to be sensitive to the antiproliferative action of silvestrol (16, 17). We found that several of these rocaglates maintained potent growth inhibition comparable with silvestrol. In particular, the IC50 values of Roc were slightly higher than silvestrol, whereas DDR reliably demonstrated approximately 2-fold more potent than silvestrol in all cell lines tested (Fig. 1; Table 1; and Supplementary Fig. S1), indicating that the dioxanyl moiety is dispensable for cytotoxicity. Further structure–activity comparison discerned some positions on the cyclopenta[b]benzofuran scaffold that affected the antiproliferative activity of rocaglates. Similar to previous observations, the substitution of a methoxy group at position 8b, as in 8b-O-methylrocaglaol versus rocaglaol, abolished the activity (Fig. 1). This methoxy substitution at 8b could be partly mitigated by the addition of a methylenedioxy ring to phenyl ring B. In addition, the presence of amide or ester groups at position C-2 of the benzofuran scaffold appeared to enhance the activity, as compounds such as DDR, Roc, and methyl rocaglate were more potent than rocaglaol. Because the amide group at the C-2 position confers superior growth inhibition, we further evaluated DDR and Roc for their mechanisms of action.

Figure 1.
Figure 1.

Identification of DDR and Roc with potent growth-inhibitory activity comparable with silvestrol. The structure of each rocaglate is shown along with its IC50 value in STS26T MPNST cells as determined in Table 1. Structure–activity comparison revealed that the dioxanyl (dioxanyloxy) ring is dispensable but may enhance the cytotoxicity of rocaglates. An unmethylated C-8b hydroxyl group (arrow) and the amide functionality (rectangle) of DDR and Roc are important for optimum antiproliferative activity, whereas methylation of the C-8b hydroxyl group (oval) substantially impaired the activity.

View this table:
Table 1.

The growth-inhibitory activity of silvestrol and 10 related rocaglates lacking the dioxanyl ring in NF1+/+ STS26T and NF1−/− ST8814 MPNST, Nf2−/− schwannoma, and NF2−/− meningioma cells.

Rocaglamides induce G2–M arrest and cell death

Flow cytometry analysis revealed that human NF1-expressing STS26T and NF1-null ST8814 MPNST cells treated with one- or two-IC50 doses of DDR or Roc for 3 days exhibited a marked increase in the G2–M fraction (Supplementary Fig. S2A and S2B). The sub-G1 fraction, suggestive of apoptosis, was noticeably prominent in treated STS26T cells, especially at the two-IC50 dose (Supplementary Fig. S2A). Phase contrast micrographs taken of cells prior to cell-cycle analysis showed increased floating dead cells and debris in DDR- or Roc-treated dishes. Although ST8814 cells treated for 3 days did not show obvious signs of cell death (Supplementary Fig. S2B), a 6-day incubation resulted in increased numbers of floating dead cells with a commensurate expansion of the sub-G1 fraction (Supplementary Fig. S2C). Collectively, these results indicate that, like silvestrol (16), DDR and Roc inhibit MPNST cell proliferation by inducing cell-cycle arrest at G2–M and subsequently, cell death.

DDR and Roc increase caspase and PARP cleavage and activate the DNA damage response, while suppressing mitogenic signaling pathways

To confirm induction of apoptosis in Roc-treated MPNST cells, we analyzed protein expression of several markers important for this process. STS26T cells treated for 3 days with either DDR or Roc exhibited increased cleavage of the executioner caspases-3 and 7 and their downstream substrate PARP (Fig. 2A). A concomitant decrease in the amounts of intact caspases 3 and 7 and PARP was observed, consistent with the enhanced cleavage of these apoptotic markers and possibly due to direct effects of these rocaglamides on protein translation. Likewise, the levels of the prosurvival kinases AKT and ERK1/2 were diminished in Roc- and DDR-treated MPNST cells. Importantly, treatment with rocaglamides also resulted in higher levels of the DNA damage response marker γH2A.X. This increase occurred as early as one day after DDR treatment before the occurrence of cell death (Fig. 2B). Similarly, cleavage of caspase-3 and PARP and induction of γH2A.X were also detected in NF1-null ST8814 cells treated with DDR and Roc (Supplementary Fig. S3). These results demonstrate that DDR and Roc induce apoptosis in both NF1-expressing and NF1-deficient MPNST cells, possibly subsequent to the activation of the DNA damage response.

Figure 2.
Figure 2.

DDR and Roc increase caspase and PARP cleavage and elevate the levels of γH2A.X while decreasing AKT and ERK expression in MPNST cells. A, Protein lysates prepared from STS26T cells treated for 3 days with 1- or 2-IC50 of DDR or Roc were analyzed by Western blots for full-length and cleaved caspase-3/7 and PARP, as well as AKT and ERK1/2. GAPDH served as a loading control. B, Protein lysates from STS26T cells treated for 1 and 2 days with 1- or 2-IC50 of DDR were probed for the expression of phosphorylated H2A.X (γH2A.X). As a positive control, lysates from HMS-97 human malignant schwannoma cells irradiated with 4 grays (Gy) of X-ray (rad) were used.

Rocaglamides are not sensitive to MDR1 inhibition, and Roc is orally bioavailable

The MDR1/P-glycoprotein (Pgp) encoded by the ABCB1 (ATP-binding cassette subfamily B member 1) gene is implicated in limiting the bioavailability of several chemotherapeutics and confers drug resistance in tumors that overexpress this protein. Silvestrol is a substrate of MDR1/Pgp, which may be related to its poor oral bioavailability (29, 30). To determine whether there are any differences in the sensitivity to MDR1/Pgp between rocaglamides and silvestrol, we treated silvestrol-resistant 697-R leukemic cells, which overexpress MDR1/Pgp (Supplementary Fig. S4), and the parental silvestrol-sensitive 697 cells with various concentrations of each compound. Similar to previous findings (29), we found that 697-R cells were less sensitive to silvestrol inhibition than 697 cells (26 vs. 3.5 nmol/L of IC50, respectively; Fig. 3A). Surprisingly, DDR- and Roc-treated 697-R cells exhibited IC50 values very similar to those of parental 697 cells (4 vs. 3 nmol/L of IC50, respectively, for DDR and 15 vs. 8 nmol/L of IC50, respectively, for Roc; Fig. 3B and C). Also, we observed that various MPNST cell lines expressed different levels of MDR1 protein (Supplementary Fig. S4). For example, ST8814 cells expressed a higher level of MDR1 than STS26T cells. Curiously, both cell lines showed similar sensitivity to growth inhibition by DDR and Roc (Table 1; Supplementary Fig. S1). Together, these results indicate that these rocaglamides are no longer sensitive to MDR1 inhibition.

Figure 3.
Figure 3.

Unlike silvestrol, DDR and Roc inhibit proliferation of MDR1-overexpressing 697-R leukemic cells at IC50 values similar to parental 697 cells. Cell proliferation was measured on 697-R and 697 cells treated for 3 days with various concentrations of silvestrol (A), DDR (B), and Roc (C). Each treatment was performed in six replicates, and each experiment was repeated twice. Shown are representative dose–response growth inhibition curves for all three drugs from experiments run in parallel. The insets show the IC50 values for each compound.

To examine the oral bioavailability, we conducted pharmacokinetic (PK) studies to compare mice that had been dosed with Roc at 5 mg/kg via the i.v., i.p., or p.o. route, followed by measuring Roc concentrations in blood samples collected at various times post dosing. Two separate studies with 3 mice at each time point for each dosing route were conducted. The maximum mean observed concentration (Cmax) reached approximately 11 μmol/L for the i.v. route, approximately 4 μmol/L for the i.p. route, and approximately 0.8 μmol/L for the p.o. route (Fig. 4A). Areas under the plasma concentration-time curves (AUC0–7h) produced 245 μmol/L*min of exposure in the i.v. route and 142 μmol/L*min of exposure in the p.o. route. The concentrations of Roc appeared to decline more slowly in the plasma over 24 hours (T½ = 2.4h) with the p.o. route compared with those dosed by the i.v. route (T½ = 1.5h). Based on the estimation from AUC0–7h, Roc exhibited approximately 50% oral bioavailability, confirming improved bioavailability of Roc over silvestrol.

Figure 4.
Figure 4.

Roc has 50% oral bioavailability and potently suppresses the growth of orthotopic MPNST xenografts. A, Plasma concentration-time profiles of Roc were obtained by PK analysis according to Materials and Methods. The mean concentration of Roc with SD in mouse plasma for each time point after i.v., i.p., and p.o. administration was plotted. For each dosing route, two independent studies were performed. B, Shown are representative BL images of ST8814-Luc MPNST-bearing mice prior to (PreTx) and 4 weeks (wks) after treatment with Roc at 4 mg/kg by i.p., 1.2 mg/kg by p.o., or HPβCD vehicle every other day. C, The relative tumor-emitted BL signals were denoted as percentage of total flux after treatment relative to the total flux prior to treatment designated as one (100%). The data are shown as mean ± SD. For each treatment group, at least 7 mice completed the full treatment schedule. Note that tumor bioluminescence from vehicle-treated mice rapidly increased by an average of approximately 17,000-fold over 4 weeks. However, tumor bioluminescence from the Roc i.p. group grew only by approximately 3-fold and from the Roc p.o. group increased approximately 470-fold on average. D, H&E staining shows that although vehicle-treated xenografts contained large vesicular nuclei with prominent nucleoli and mitotic activity, tumors treated with Roc by i.p. had pleomorphic nuclei, and many enlarged tumor cells had abundant foamy cytoplasm resembling histiocytoid degenerative changes along with scattered apoptosis (top panels). Degenerative tumor cells were also present in tumors treated with orally delivered Roc. Tumor necrosis with necrotic debris separating mostly degenerative tumor cells with viable vasculature was also observed. Immunostaining revealed abundant phospho-histone H3 (pH3)–labeled cells in Roc-treated tumors compared with vehicle-treated tumors (middle panels). Increased numbers of cleaved caspase-3 (CC3)–positive cells were detected in Roc-treated tumors (bottom panels).

Roc, when administered intraperitoneally or orally, exhibits potent antitumor effects in an orthotopic MPNST model

To evaluate the in vivo activity of Roc, we treated NSG mice bearing luciferase-expressing ST8814-Luc tumors implanted in the sciatic nerve with Roc at the predetermined MTD (4 mg/kg by i.p. or 1.2 mg/kg orally), or HPβCD vehicle every other day. As shown in Fig. 4B and C, tumor bioluminescence from vehicle-treated mice steadily and rapidly increased by >10,000-fold over 4-week treatment. In contrast, tumor bioluminescence from mice treated with Roc by i.p. only increased by an average of <10-fold, showing >99% reduction in tumor luminescence compared with controls. Similarly, Roc, when administered orally, also exhibited potent tumor inhibition with bioluminescence decreasing by >95%. In addition, we did not observe any significant changes in body weight of animals treated with the indicated doses of Roc, compared with vehicle-treated controls (Supplementary Fig. S5).

Histologic analysis revealed that although MPNSTs treated with HPβCD vehicle for 4 weeks had large nuclei with prominent nucleoli and displayed active mitotic figures (Fig. 4D, top left panel), tumors treated with Roc by i.p. had pleomorphic nuclei with abundant foamy cytoplasm resembling histiocytoid degenerative changes (top middle panel). A few enlarged tumor cells with multinucleated appearance and scattered apoptosis were present. Degenerative changes and cell death were also observed in tumors treated with orally delivered Roc (top right panel). Consistent with G2–M arrest, tumor cells treated with i.p. or orally delivered Roc exhibited much higher prevalence of phospho-histone H3 labeling compared with vehicle-treated tumors (middle panel). In addition, Roc-treated tumors displayed increased numbers of cleaved caspase-3–positive cells which often coincided with those with multinucleated-like appearance (bottom panel). Taken together, these results indicate that Roc has oral bioavailability and possesses potent in vivo efficacy against MPNSTs.

Roc and DDR have broad antitumor activity against common types of pediatric sarcoma

Because MPNSTs comprise only approximately 2% of all sarcomas (34), we expanded our testing of Roc and DDR to three other types of sarcomas more prevalently seen in children and young adults: Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma. Using a series of commonly used cell lines, including two Ewing sarcoma cell lines (A673 and TC32), four osteosarcoma cell lines (143B, MG-63, Saos2, and OS17), and one rhabdomyosarcoma cell line (RD), we showed that, as in MPNST cells, both rocaglamides were highly active against all of these sarcoma cell lines (Supplementary Fig. S6A–S6C). Also, we observed that DDR consistently exhibited lower IC50 values than Roc in every sarcoma cell line tested.

Subsequently, we evaluated the in vivo activity of Roc using PDX models for a Ewing sarcoma, an osteosarcoma, and an alveolar rhabdomyosarcoma. We discovered that Roc was highly potent in suppressing the growth of Ewing sarcoma PDXs and inhibited tumor growth by an average of approximately 90% over 4-week treatment (Fig. 5A). Similarly, the average size of Roc-treated osteosarcoma PDX tumors was reduced by approximately 80% compared with those of vehicle-treated tumors (Fig. 5B). Also, Roc inhibited the growth of rhabdomyosarcoma PDXs by approximately 70% (Fig. 5C). Notably, the volumes of tumors in individual Roc-treated mice showed very little overlap with those in vehicle-treated mice, particularly for the Ewing sarcoma and osteosarcoma PDX models (Fig. 5). Together with the findings from the MPNST model, these results demonstrate that Roc displays significant antitumor effects against multiple types of sarcoma.

Figure 5.
Figure 5.

Roc exhibits potent antitumor effects in multiple sarcoma PDX models. Mice with growing Ewing sarcoma (A), osteosarcoma (B), and rhabdomyosarcoma (C) PDXs were treated with 3 mg/kg of Roc or HPβCD vehicle by i.p. every other day. Tumor diameters were measured twice weekly, and volumes calculated according to Materials and Methods. The normalized tumor volume, denoted as the ratio of the calculated tumor volume after treatment relative to the volume prior to treatment designated as one, was plotted as the mean tumor volume of the entire treatment group at each time point with SD (left panels). The calculated tumor volume for each individual mouse over time was also plotted (right panels).

Rocaglamides decrease multiple signaling kinases and transcription factors important for sarcoma cell growth

To further examine the molecular mechanisms underlying the antiproliferative effects of rocaglamides, we treated TC32 Ewing sarcoma, 143B osteosarcoma, and RD rhabdomyosarcoma cells with one- or two-IC50 dose of DDR or Roc for 1 to 2 days followed by Western blotting for several known drivers of cell survival and proliferation. Interestingly, we found that these rocaglamides reliably reduced the levels of the β subunit of IGF-1R, an upstream activator of PI3K–AKT signaling, in all three sarcoma cell lines (Fig. 6A–C). We also observed reduction of the IGF-1Rβ levels in Roc-treated MPNST cells (Supplementary Fig. S7). In addition, both rocaglamides decreased the levels of AKT, ERKs, cyclin D1 and survivin in treated TC32, 143B, and RD cells (Fig. 6). Intriguingly, the oncogenic fusion protein EWS-FLI1, which acts as an aberrant transcription factor in Ewing sarcoma (35), was not affected in Roc- and DDR-treated TC32 Ewing sarcoma cells (Fig. 6A). Consistent with this observation, these rocaglamides did not inhibit EWS expression in 143B osteosarcoma and RD rhabdomyosarcoma cells (Fig. 6B and C). However, the levels of lysine demethylase 1 (LSD1), which modulates EWS-FLI1 transcriptional activity (36), and NKX2.2, an EWS-FL11–regulated gene necessary for oncogenic transformation (37), were diminished by these rocaglamides in TC32 cells (Fig. 6A). Collectively, these results suggest that rocaglamides potently suppress sarcoma growth by decreasing multiple key signaling proteins important for tumor growth and survival.

Figure 6.
Figure 6.

DDR and Roc reduce multiple signaling proteins important for sarcoma cell growth and survival. Protein lysates from TC32 Ewing sarcoma (A), 143B osteosarcoma (B), and RD rhabdomyosarcoma (C) cells treated for 1 and 2 days with the indicated concentrations of DDR or Roc were analyzed by Western blotting for various oncogenic driver proteins. GAPDH was used as a loading control.

Comparative toxicology studies in canines show that Roc does not induce pulmonary toxicity found with silvestrol

As the next part of the standard process for developing compounds as candidates for human evaluation, a toxicology study in dogs was conducted through a contractor of the NCI Experimental Therapeutics program. Unexpectedly, silvestrol was found to cause massive lung damage, whereas Roc did not produce adverse pulmonary findings when tested on the same protocol at the same lab. Further details are contained in the online summary reports for both silvestrol and Roc at https://dtp.cancer.gov/publications/silvestrol_rocaglamide_studies.pdf.

Discussion

For decades, treatments for MPNSTs and other sarcomas have remained largely unchanged with current standard of care combining surgical resection with intensive multiagent chemotherapy (1, 34, 38, 39). Radiation may be used depending upon the tumor type and clinical presentation. Although this multidisciplinary treatment strategy may help local control, it is not effective for metastatic and recurrent disease. Also, these multimodal regimens are associated with considerable acute and long-term toxicities that affect patients' quality of life. Despite recent advances in understanding tumor biology and targeted therapy development, an FDA-approved medical therapy for the treatment of these malignancies is still not available. We previously showed that eIF4A is a vulnerable point of disruption in MPNSTs and that the eIF4A inhibitor silvestrol potently suppresses MPNST growth (16). Regretfully, silvestrol exhibited an unexpected pulmonary toxicity in dogs, and its further development as a cancer therapy was suspended (D.M. Lucas, M.A. Phelps, A.D. Kinghorn, M. Grever; in preparation). We have identified two rocaglates lacking the dioxanyl ring, Roc and DDR, with better drug-like properties than silvestrol and possessing antitumor efficacy in multiple sarcoma models, including MPNST. Most critically, Roc did not induce the toxicity found in dogs with silvestrol under the same conditions.

Our side-by-side comparison of ten rocaglates lacking the bulky dioxanyl ring present in silvestrol has allowed us to discern certain structure–activity relationships, particularly the C-8b, C-2, and C-6 positions along the cyclopenta[b]benzofuran core. Consistent with previous reports (22, 40), the hydroxy group at the C-8b position is essential for antiproliferative activity. This finding is consistent with the crystal structure of Roc complexed with eIF4A and polypurine RNA, which reveals hydrogen bonding between the 8b-OH of Roc and a guanine base in the RNA (41). Also, the phenyl rings A and B of Roc parallel stack with RNA bases, which may explain our finding that adding a methylenedioxy group to ring B modestly improved the growth-inhibitory activity of rocaglates with methylated 8b-OH (Fig. 1). It is possible that this methylenedioxy ring may enhance the affinity of the rocaglates to the eIF4A-RNA complex, partially compensating for the loss of 8b hydrogen bonding.

Among the rocaglates lacking the dioxanyl ring that we evaluated, DDR was the most potent, suggestive of the importance of having a simple primary amide group at the C-2 position. Although the presence of a dioxanyl ring instead of a methoxy group at the C-6 position enhances the potency of silvestrol compared with methyl rocaglate (22, 42), our data indicated that this ring is not required for cytotoxicity. However, it appears to play an important role in MDR1-induced resistance as Roc and DDR are no longer susceptible to this inhibitory effect. Consistent with this notion, we detected a higher level of MDR1 in ST8814 MPNST cells than that in STS26T cells (Supplementary Fig. S4), whereas the IC50 values of Roc and DDR in ST8814 cells were similar to those in STS26T cells (Table 1; Supplementary Fig. S1). The MDR1 transporter binds to silvestrol and is thought to limit its oral bioavailability (29). Our PK analysis demonstrating 50% oral bioavailability of Roc, a >25-fold improvement over silvestrol, confirms this prediction and strongly suggests a possible interaction of MDR1 with the dioxanyl moiety. The observed oral bioavailability of Roc allows a greater flexibility for dosing. More importantly, we found that Roc, when administered i.p. or p.o., showed potent antitumor effects in an orthotopic MPNST CDX mouse model and effectively suppressed the growth of PDX models for Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

Like silvestrol, rocaglamides exert their potent growth-inhibitory and antitumor activities mainly through inhibition of eIF4A and protein translation (43, 44). Consistently, we observed that Roc and DDR decreased the levels of multiple signaling proteins important for tumor growth and survival, leading to G2–M cell-cycle arrest and activation of executioner caspases. In addition to AKT and ERKs, rocaglamides reduced the levels of IGF-1R in all sarcoma cell lines tested. This decrease in IGF-1R expression, coupled with the simultaneous inhibition of AKT and ERKs, likely results in superior inhibition of IGF-1 signaling compared with the simple blockade at the receptor level. Our results further suggest that IGF-1R may serve as a biomarker for responsiveness to rocaglamides in sarcomas.

It should be noted that the effects of translation inhibition mediated by eIF4A are different from those by eIF4E, which can be activated by the AKT/mTOR pathway, a commonly deregulated event in sarcomas (18). The mTOR inhibitor, rapamycin and its analogs, and mTOR kinase inhibitors only cause cytostatic effects and tumor stabilization (45). Also, blocking mTOR signaling is associated with activation of bypass signaling pathways that can restore critical survival signals, enabling tumor regrowth. Inhibition of eIF4E tends to decrease translation of the mRNAs with 5′ terminal oligopyrimidine tracts, which encode ribosomal proteins, elongation factors, lysosomal-related and metabolic-related proteins. However, the eIF4A activity is more critical in unwinding the mRNAs with long 5′-UTRs that can form G-quadruplexes, such as AKT and IGF-1R (15, 20). In addition, some transcripts, e.g., c-MYC, are translated from internal ribosomal entry sites that do not require the cap binder eIF4E and are insensitive to eIF4E inhibition (46). Thus, blocking eIF4A may have a stronger effect on tumor growth and survival.

Ewing sarcoma is frequently driven by the chimeric fusion oncogene EWS-FLI1 due to a chromosomal translocation that fuses an RNA-binding protein, EWSR1, with the FLI1 transcription factor (35). Surprisingly, we found that the levels of EWS-FLI1 remained unchanged in Roc-treated Ewing sarcoma cells (Fig. 6A). As a ubiquitously expressed protein, the EWSR1 levels were also not affected in other types of sarcoma cells treated with rocaglamides (Fig. 6B and C). In contrast, the levels of the epigenetic modulator LSD1, a protein needed for optimal activity of the EWS-FLI1 transcriptional complex (36), and a key EWS-FLI1 downstream target NKX2.2, a homeobox transcription factor implicated in development (37), were diminished by DDR and Roc treatment (Fig. 6). Upon inspection of these genes, we noted that the EWSR1 transcript has a very short 5′-UTR, whereas the mRNAs for NKX2.2 and LSD1/KDM1A contain longer G+C-rich 5′-UTRs. Therefore, we hypothesize that the NKX2.2 and LSD1/KDM1A transcripts are eIF4A-dependent.

Intriguingly, prior to caspase activation, Roc-treated MPNST cells exhibited increased γH2A.X, suggesting that DNA damage may be a key underlying cause of the apoptosis seen at later time points. Rocaglamides may affect prohibitin-mediated ERK activation, cause the disruption of mitochondrial integrity, and/or promote the generation of reactive oxygen species (47, 48). Alternatively, they may affect translation of the proteins responsible for DNA replication and repair, resulting in stalled replication forks or inadequate repair of DNA damage. We are presently examining these possibilities.

Roc was the first member of the cyclopenta[b]benzofuran class identified as a novel antileukemic agent from Aglaia elliptifolia by King and colleagues (49). It is worth mentioning that the structures of Roc and DDR are simpler than silvestrol; therefore, they should be more amenable to chemical synthesis (50). As DDR exhibited higher in vitro potency against various types of sarcoma cells than Roc, we anticipate that DDR will have superior antitumor efficacy. Experiments are in progress to compare these rocaglamides in various sarcoma animal models.

In summary, we have demonstrated that Roc and DDR, as eIF4A inhibitors, simultaneously suppressed multiple growth-promoting signaling pathways and induced apoptosis in tumor cells. Roc was no longer sensitive to MDR1 inhibition. It was orally bioavailable and exhibited potent antitumor effects in multiple sarcoma models with no overt toxicity. These promising results indicate that these rocaglamides merit further investigation as treatments for patients with MPNSTs and other sarcomas.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: L.-S. Chang, J.L. Oblinger, S.S. Burns, J.M. Collins

Development of methodology: L.-S. Chang, J.L. Oblinger, S.S. Burns, J. Huang, L.W. Anderson, R.D. Roberts

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L.-S. Chang, J.L. Oblinger, S.S. Burns, J. Huang, L.W. Anderson, M.G. Hollingshead, R. Shen, G. Agarwal, R.D. Roberts

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L.-S. Chang, J.L. Oblinger, S.S. Burns, L.W. Anderson, M.G. Hollingshead, R. Shen, R.D. Roberts, J.M. Collins

Writing, review, and/or revision of the manuscript: L.-S. Chang, J.L. Oblinger, L.W. Anderson, M.G. Hollingshead, Y. Ren, R.D. Roberts, B.R. O'Keefe, A.D. Kinghorn

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.-S. Chang, J.L. Oblinger, S.S. Burns, L. Pan, J.M. Collins

Study supervision: L.-S. Chang, B.R. O'Keefe, A.D. Kinghorn, J.M. Collins

Other (isolated and identified the test compounds, rocaglamide, and didesmethylrocaglamide): L. Pan

Acknowledgments

We thank Melissa Sammons of NCH Tumor Core for assistance with PDX models, Eva Majerova for technical help with plasma analysis, John Byrd for 697 and 697-R cells, Stephen Lessnick for Ewing sarcoma cells, and Ruoning Wang for rhabdomyosarcoma cells.

This study was supported by grants from CancerFree KIDS, Sunbeam Foundation, and Department of Defense (W81XWH-16-1-0104 and W81XWH-18-1-0547 to L.-S. Chang), National Cancer Institute (P01CA125066 to A.D. Kinghorn and P30CA16058 to The OSU Comprehensive Cancer Center), and NCI Experimental Therapeutics program (NCI Contract HHSN261200800001 to Leidos Biomedical Research).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

  • Mol Cancer Ther 2020;19:731–41

  • Received August 19, 2019.
  • Revision received December 2, 2019.
  • Accepted December 13, 2019.
  • Published first December 17, 2019.

References

  1. 1.↵
    1. Kim A,
    2. Stewart DR,
    3. Reilly KM,
    4. Viskochil D,
    5. Miettinen MM,
    6. Widemann BC
    . Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma 2017;2017:7429697.
    OpenUrlCrossRef
  2. 2.↵
    1. Perrone F,
    2. Da Riva L,
    3. Orsenigo M,
    4. Losa M,
    5. Jocollè G,
    6. Millefanti C,
    7. et al.
    PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 2009;11:725–36.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Yang J,
    2. Ylipää A,
    3. Sun Y,
    4. Zheng H,
    5. Chen K,
    6. Nykter M,
    7. et al.
    Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res 2011;17:7563–73.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kim A,
    2. Pratilas CA
    . The promise of signal transduction in genetically driven sarcomas of the nerve. Exp Neurol 2018;299(Pt B):317–25.
    OpenUrl
  5. 5.↵
    1. De Raedt T,
    2. Beert E,
    3. Pasmant E,
    4. Luscan A,
    5. Brems H,
    6. Ortonne N,
    7. et al.
    PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014;514:247–51.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Sebti SM,
    2. Tkalcevic GT,
    3. Jani JP
    . Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun 1991;3:141–7.
    OpenUrlPubMed
  7. 7.↵
    1. Barkan B,
    2. Starinsky S,
    3. Friedman E,
    4. Stein R,
    5. Kloog Y
    . The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006;12:5533–42.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Rao S,
    2. Cunningham D,
    3. de Gramont A,
    4. Scheithauer W,
    5. Smakal M,
    6. Humblet Y,
    7. et al.
    Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22:3950–7.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Cloughesy TF,
    2. Wen PY,
    3. Robins HI,
    4. Chang SM,
    5. Groves MD,
    6. Fink KL,
    7. et al.
    Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24:3651–6.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Hanrahan EO,
    2. Kies MS,
    3. Glisson BS,
    4. Khuri FR,
    5. Feng L,
    6. Tran HT,
    7. et al.
    A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009;3:274–9.
    OpenUrl
  11. 11.↵
    1. Albritton KH,
    2. Rankin C,
    3. Coffin CM,
    4. Ratner N,
    5. Budd GT,
    6. Schuetze SM,
    7. et al.
    Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2006;24 Suppl 18:9518.
  12. 12.↵
    1. Tap WD,
    2. Demetri G,
    3. Barnette P,
    4. Desai J,
    5. Kavan P,
    6. Tozer R,
    7. et al.
    Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 2012;30:1849–56.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Maki RG,
    2. D'Adamo DR,
    3. Keohan ML,
    4. Saulle M,
    5. Schuetze SM,
    6. Undevia SD,
    7. et al.
    Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133–40.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Widemann BC,
    2. Meyer CF,
    3. Cote GM,
    4. Chugh R,
    5. Milhem MM,
    6. Van Tine BA,
    7. et al.
    SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2016;34 Suppl 15:11053.
    OpenUrl
  15. 15.↵
    1. Malka-Mahieu H,
    2. Newman M,
    3. Désaubry L,
    4. Robert C,
    5. Vagner S
    . Molecular pathways: the eIF4F translation initiation complex-new opportunities for cancer treatment. Clin Cancer Res 2017;23:21–5.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Oblinger JL,
    2. Burns SS,
    3. Akhmametyeva EM,
    4. Huang J,
    5. Pan L,
    6. Ren Y,
    7. et al.
    Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro-Oncol 2016;18:1265–77.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Oblinger JL,
    2. Burns SS,
    3. Huang J,
    4. Pan L,
    5. Ren Y,
    6. Shen R,
    7. et al.
    Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 2018;299(Pt B):299–307.
    OpenUrlCrossRef
  18. 18.↵
    1. Mamane Y,
    2. Petroulakis E,
    3. LeBacquer O,
    4. Sonenberg N
    . mTOR, translation initiation and cancer. Oncogene 2006;25:6416–22.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Chu J,
    2. Cargnello M,
    3. Topisirovic I,
    4. Pelletier J
    . Translation initiation factors: reprogramming protein synthesis in cancer. Trends Cell Biol 2016;26:918–33.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Wolfe AL,
    2. Singh K,
    3. Zhong Y,
    4. Drewe P,
    5. Rajasekhar VK,
    6. Sanghvi VR,
    7. et al.
    RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014;513:65–70.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Pan L,
    2. Woodard JL,
    3. Lucas DM,
    4. Fuchs JR,
    5. Kinghorn AD
    . Rocaglamide, silvestrol, and related bioactive compounds from Aglaia species. Nat Prod Rep 2014:31;924–31.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Kinghorn AD,
    2. DE Blanco EJ,
    3. Lucas DM,
    4. Rakotondraibe HL,
    5. Orjala J,
    6. Soejarto DD,
    7. et al.
    Discovery of anticancer agents of diverse natural origin. Anticancer Res 2016;36:5623–37.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Lucas DM,
    2. Edwards RB,
    3. Lozanski G,
    4. West DA,
    5. Shin JD,
    6. Vargo MA,
    7. et al.
    The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009;113:4656–66.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Kogure T,
    2. Kinghorn AD,
    3. Yan I,
    4. Bolon B,
    5. Lucas DM,
    6. Grever MR,
    7. et al.
    Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One 2013;8:e76136.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Boussemart L,
    2. Malka-Mahieu H,
    3. Girault I,
    4. Allard D,
    5. Hemmingsson O,
    6. Tomasic G,
    7. et al.
    eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 2014;513:105–9.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. El Sous M,
    2. Khoo ML,
    3. Holloway G,
    4. Owen D,
    5. Scammells PJ,
    6. Rizzacasa MA
    . Total synthesis of (−)-episilvestrol and (−)-silvestrol. Angew Chem Int Ed Engl 2007;46:7835–8.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Gerard B,
    2. Cencic R,
    3. Pelletier J,
    4. Porco JA Jr.
    . Enantioselective synthesis of the complex rocaglate (-)-silvestrol. Angew Chem Int Ed Engl 2007;46:7831–4.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Adams TE,
    2. El Sous M,
    3. Hawkins BC,
    4. Hirner S,
    5. Holloway G,
    6. Khoo ML,
    7. et al.
    Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (−)-episilvestrol and the active analogue (−)-4′-desmethoxyepisilvestrol. J Am Chem Soc 2009;131:1607–16.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Gupta SV,
    2. Sass EJ,
    3. Davis ME,
    4. Edwards RB,
    5. Lozanski G,
    6. Heerema NA,
    7. et al.
    Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J 2011;13:357–64.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Saradhi UV,
    2. Gupta SV,
    3. Chiu M,
    4. Wang J,
    5. Ling Y,
    6. Liu Z,
    7. et al.
    Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J 2011;13:347–56.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Pan L,
    2. Acuña UM,
    3. Li J,
    4. Jena N,
    5. Ninh TN,
    6. Pannell CM,
    7. et al.
    Bioactive flavaglines and other constituents isolated from Aglaia perviridis. J Nat Prod 2013;76:394–404.
    OpenUrl
  32. 32.↵
    1. Burns SS,
    2. Akhmametyeva EM,
    3. Oblinger JL,
    4. Bush ML,
    5. Huang J,
    6. Senner V,
    7. et al.
    Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res 2013;73:792–803.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Burns SS,
    2. Chang LS
    . Generation of noninvasive, quantifiable, orthotopic animal models for NF2-associated schwannoma and meningioma. Methods Mol Biol 2016;1427:59–72.
    OpenUrl
  34. 34.↵
    1. Farid M,
    2. Demicco EG,
    3. Garcia R,
    4. Ahn L,
    5. Merola PR,
    6. Cioffi A,
    7. et al.
    Malignant peripheral nerve sheath tumors. Oncologist 2014;19:193–201.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Delattre O,
    2. Zucman J,
    3. Plougastel B,
    4. Desmaze C,
    5. Melot T,
    6. Peter M,
    7. et al.
    Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162–5.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Sankar S,
    2. Bell R,
    3. Stephens B,
    4. Zhuo R,
    5. Sharma S,
    6. Bearss DJ,
    7. et al.
    Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 2013;32:5089–100.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Smith R,
    2. Owen LA,
    3. Trem DJ,
    4. Wong JS,
    5. Whangbo JS,
    6. Golub TR,
    7. et al.
    Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405–16.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Brown HK,
    2. Schiavone K,
    3. Gouin F,
    4. Heymann MF,
    5. Heymann D
    . Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int 2018;102:174–95.
    OpenUrl
  39. 39.↵
    1. Skapek SX,
    2. Ferrari A,
    3. Gupta AA,
    4. Lupo PJ,
    5. Butler E,
    6. Shipley J,
    7. et al.
    Rhabdomyosarcoma. Nat Rev Dis Primers 2019;5:1.
    OpenUrl
  40. 40.↵
    1. Ebada SS,
    2. Lajkiewicz N,
    3. Porco JA Jr.,
    4. Li-Weber M,
    5. Proksch P
    . Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from Aglaia species (Meliaceae). Prog Chem Org Nat Prod 2011;94:1–58.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Iwasaki S,
    2. Iwasaki W,
    3. Takahashi M,
    4. Sakamoto A,
    5. Watanabe C,
    6. Shichino Y,
    7. et al.
    The translation inhibitor rocaglamide targets a bimolecular cavity between eIF4A and polypurine RNA. Mol Cell 2019;73:738–48.
    OpenUrl
  42. 42.↵
    1. Kim S,
    2. Salim AA,
    3. Swanson SM,
    4. Kinghorn AD
    . Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem 2006;6:319–45.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Cencic R,
    2. Carrier M,
    3. Galicia-Vázquez G,
    4. Bordeleau ME,
    5. Sukarieh R,
    6. Bourdeau A,
    7. et al.
    Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS One 2009;4:e5223.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Sadlish H,
    2. Galicia-Vazquez G,
    3. Paris CG,
    4. Aust T,
    5. Bhullar B,
    6. Chang L,
    7. et al.
    Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol 2013;8:1519–27.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. D'Abronzo LS,
    2. Ghosh PM
    . eIF4E phosphorylation in prostate cancer. Neoplasia 2018;20:563–73.
    OpenUrl
  46. 46.↵
    1. Wiegering A,
    2. Uthe FW,
    3. Jamieson T,
    4. Ruoss Y,
    5. Hüttenrauch M,
    6. Küspert M,
    7. et al.
    Targeting translation initiation bypasses signaling crosstalk mechanisms that maintain high MYC levels in colorectal cancer. Cancer Discov 2015;5:768–81.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Polier G,
    2. Neumann J,
    3. Thuaud F,
    4. Ribeiro N,
    5. Gelhaus C,
    6. Schmidt H,
    7. et al.
    The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 2012;19:1093–104.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Callahan KP,
    2. Minhajuddin M,
    3. Corbett C,
    4. Lagadinou ED,
    5. Rossi RM,
    6. Grose V,
    7. et al.
    Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia 2014;28:1960–8.
    OpenUrl
  49. 49.↵
    1. King ML,
    2. Chiang CC,
    3. Ling HC,
    4. Fujita E,
    5. Ochiai M,
    6. McPhail AT
    . X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J Chem Soc, Chem Commun 1982;20:1150–1.
    OpenUrl
  50. 50.↵
    1. Liu T,
    2. Nair SJ,
    3. Lescarbeau A,
    4. Belani J,
    5. Peluso S,
    6. Conley J,
    7. et al.
    Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem 2012;55:8859–78.
    OpenUrlCrossRefPubMed
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas
Long-Sheng Chang, Janet L. Oblinger, Sarah S. Burns, Jie Huang, Larry W. Anderson, Melinda G. Hollingshead, Rulong Shen, Li Pan, Garima Agarwal, Yulin Ren, Ryan D. Roberts, Barry R. O'Keefe, A. Douglas Kinghorn and Jerry M. Collins
Mol Cancer Ther March 1 2020 (19) (3) 731-741; DOI: 10.1158/1535-7163.MCT-19-0809
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement